Skip to main content

Result releasedAnnolyse analysis published

Headline 99.9% PBT improvement masks transition to NZ$2.0m shell

Total assets fell from NZ$2,154.5m to NZ$2.0m through an issuer transition, leaving zero revenue and only NZ$22k of cash.

IPR revenue trajectory

Revenue context before the current result.

Loading chart...
FY22 was $0m, versus $0.03m in FY21.

IPR operating cash flow

Operating cash flow across covered periods.

Loading chart...
FY22 was -$0.12m, versus -$0.12m in FY21.

Market context

Valuation

These ratios pair a market close from around the result date with verified filing data. An unavailable metric means the required inputs were missing or unsuitable for comparison.

Prices as at close, 18 September 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$1.5m

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

Not available

i

Not meaningful when recent earnings are negative.

EPS

-0.00

i

Recent filing-derived earnings per share.

PEG

Not available

i

Not available for this company right now.

EV/EBITDA

Not available

i

Not meaningful when recent EBITDA is negative.

P/FCF

Not available

i

Not meaningful when free cash flow is negative or unavailable.

P/B

28.61x

i

Market value compared with latest reported equity.

Income and investment-company measures

Yield and investment-company valuation where supported.

Dividend yield

0.0%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Release date
30 May 2022
Published
23 April 2026

Key metrics

Numbers worth scanning first

FY22 vs FY21

Revenue

$0m

Caveat: metric quality flags apply; use this value with basis context.

Net profit after tax

Caveat: metric quality flags apply; use this value with basis context.

Net cash inflow from operating activities

−$0.12m

+3.7% ↑ vs −$0.12m

Cash and cash equivalents

$0.02m

-99.0% ↓ vs $2.1m

Total assets

$2m

-5.5% ↓ vs $2.2m

Analysis ofIPR FY22Result releasedAnnolyse analysis published

What changed

The most material event is an issuer transition that has reset the company to a listed shell

Total assets fell from NZ$2.2b to NZ$2.0m, equity from NZ$2.1b to NZ$1.9m, and cash from NZ$2.1b to NZ$0.022m. Revenue collapsed to zero from NZ$25.3m, which in the prior comparable was interest income on the legacy cash balance rather than operating revenue.

Against that backdrop, the headline PBT and NPAT both improved 99.9% to a NZ$0.2m loss from a NZ$117.6m loss, and operating cash outflow narrowed from NZ$123.6m to NZ$0.1m. These improvements are arithmetic consequences of the balance-sheet reset, not operating performance. The effective tax rate remained at 0.0% on both sides, so the PBT-to-NPAT read is clean but uninformative.

What matters

The 99.9% PBT improvement is scale mechanics, not an operating turnaround

  • Annolyse's historical baseline shows current total assets of NZ$2.0m sit within the company's normal shell-state range (NZ$0.5m–NZ$2.2b across the four-period window), with FY21 the outlier. This matters because the comparison flatters a company that no longer carries the cost base, capital, or revenue stream that produced the prior loss.
  • There is no operating business to analyse. Revenue is zero, cash is NZ$22k, and the cost base that generated the NZ$0.2m loss is what remains of corporate overhead. For an investor, this result describes a vehicle, not a business.
  • ROE moved from -5.7% to -8.7% on a collapsed equity base. This is "weakening" only in a technical sense — a tiny loss divided by a tiny equity number — and should not be read as deteriorating returns on a going concern.

Expectations

No targets or guidance were provided

The HY22 commentary stated the company "continues to look for appropriate acquisition targets with the support of the majority" shareholder, which is the only forward signal available. The current release does not update that stance, name a target, or quantify a funding plan.

With NZ$22k of cash and NZ$1.9m of equity, any meaningful acquisition would require fresh capital, scrip issuance, or vendor support. The result therefore supports nothing about a future business; it only confirms the shell remains intact and the search continues.

Quality of result

Durability is not the right lens here, because there is no recurring operating activity to assess

The reported NZ$0.2m loss is essentially residual corporate costs, and the narrower operating cash outflow simply reflects the absence of the prior period's wind-down distributions. Neither figure carries a read-through to a future operating margin, cash conversion, or working-capital cycle.

The cleaner takeaway is that the like-for-like comparison is not meaningful. FY21 financials describe an entity with NZ$2.15bn of assets and NZ$25.3m of interest income; FY22 describes a NZ$2.0m shell. Treating the 99.9% improvement as earnings progression would misread the filing. It is a presentational artefact of the issuer transition flagged in the supplied event overlay.

Unresolved

Open questions

What is the current acquisition pipeline, and on what timeline does the board expect a transaction?
How will any acquisition be funded given only NZ$22k of cash and NZ$1.9m of equity?
What annualised corporate cost base does the shell carry, and how long is the runway before further capital is required?
What drove the wind-down of the NZ$2.15bn legacy balance sheet during the period, and were proceeds returned to shareholders or transferred elsewhere?
Why is the listing being retained, and what is the majority shareholder's stated role in funding the next phase?

This briefing cannot assess the economics, valuation, or quality of any future acquired business, because none has been disclosed in the supplied release.

Ask about IPR FY22

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Iperion's FY22 result.

What is the current acquisition pipeline, and on what timeline does the board expect a transaction?Why does "The 99.9% PBT improvement is scale mechanics, not an operating turnaround" matter?How strong was the cash and earnings quality in FY22?What should I watch next for IPR after FY22?

Checking account...

Data appendix

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

SNC Preliminary Full Year Result 2022

FY22 / financial report

Prior comparable period

SNC Preliminary Full Year Result 2021

FY21 / financial report

Interim context

SNC 1H22 Interim Report

HY22 / financial report

SNC 1H22 NZX Results Template

HY22 / results announcement

Get notified when IPR publishes next

Get the next Iperion briefing and related NZX reporting-season updates by email.